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Adenocarcinoma of the pancreas still carries a dramatically
poor prognosis and the survival rate for this disease has not
improved substantially in the past 40 years. Therefore, new
treatment options are urgently needed and this need motivates
oncologists to search for novel approaches such as
immunotherapy. Here we report two clinical cases successfully
treated with an integrative immunotherapeutic approach based
on oleic acid bound to glycosylated vitamin D-binding protein
(OA-GcMAF). Considering that immune suppression induced
by pancreatic cancer is one of the main causes for resistance
to chemotherapy and targeted therapy, this novel
immunotherapeutic approach has the potential for
revolutionising the field of pancreatic adenocarcinoma
treatment. Introduction: Adenocarcinoma of the pancreas is,
after colorectal cancer, the second most common digestive
cancer in the USA where it represents the fourth leading cause
of cancer-related death in both genders. In Europe,
adenocarcinoma of the pancreas is the sixth most frequent
cancer and is predicted to become the fourth cause of cancer
death in both sexes in due course in the European Union (1, 2).
Patients with pancreatic adenocarcinoma have an especially
poor prognosis with a 5-year survival rate of <1% and a
median survival of 4-6 months. Patients with a metastatic
disease are usually treated with chemotherapy that is minimally
effective (3). It has been demonstrated that pancreatic cancer-
induced immune suppression is the main cause for this
dramatically poor prognosis and, therefore, it has been
proposed that immunotherapies may be particularly effective
in this type of cancer (4). We recently demonstrated that
immunotherapy based on oleic acid (OA) bound to
glycosylated vitamin D-binding protein (OA-GcMAF) is
effective in a variety of cancers (5); here we describe two
clinical cases demonstrating that OA-GcMAF has therapeutic
efficacy also in pancreatic adenocarcinomas. Patients and
Methods: Patients with adenocarcinoma of the pancreas were
treated with OA-GcMAF-based integrative immunotherapy
according to the “Good practice in prescribing and managing
medicines and devices” effective February 2013. The
approaches described below, aimed at strengthening the
immune system and reducing tumour growth, are considered
complementary to other anti-neoplastic therapeutic procedures.
OA-GcMAF complexes (GOleic) were prepared in-house at
Immuno Biotech Ltd as previously described (5). The protocol
for pancreatic adenocarcinoma was the following: OA-GcMAF
(880 ng/day) was administered by subcutaneous injections in
proximity of the inguinal lymphnodes (440 ng in each side)
under ultrasound guidance. OA-GcMAF (880 ng) was also
administered daily by nebulisation (880 ng dissolved in 5 ml
saline). Suppositories containing 200 ng OA-GcMAF were
administered daily. The total amount of daily OA-GcMAF was
1960 ng, an amount consistent with the procedure described by
Nonaka et al. (6). Patients were provided with supplementation
of vitamin D3, 20.000 IU per day, and they were taught to
drink at least 2 litres of water per day. Patients followed a
nutritional regime based on a diet very low in carbohydrates,
and high in proteins (7). This regimen included
supplementation with essential aminoacids (Master Aminoacid
Pattern, dr. reinwald healthcare gmbh, Schwarzenbruck,
Germany). Considering that probiotics are efficient
immunopotentiators and have a role in cancer prevention (8),
patients were provided with a probiotic fermented milk product
containing colostrum and microorganisms known to produce
natural OA-GcMAF during the fermentation process (Bravo
Probiotic, Les Alpes, Wellington, NZ). Finally, considering the
role of low-dose acetylsalicylic acid in cancer prevention (9),
patients were provided with 100 mg of such a principle per
day. Results: Clinical case #1. A 58-year-old lady was
diagnosed with pancreatic adenocarcinoma localised in the
body of the pancreas. The lesion could be detected by
ultrasonography and it appeared as a roundish mass of 0.924
ml of calculated volume (Figure 1A). After two weeks of
treatment as described above, the calculated volume of the
mass was reduced to 0.517 ml that is about 39% (Figure 1B).
The patient did not report any side effect: her body weight and
lean mass increased during the two weeks of treatment.
Clinical case #2. A 73-year-old man was diagnosed with
metastatic pancreatic adenocarcinoma. Previous CT scans had
evidenced peritoneal metastases. The patient was overweight
and presented with an insulin-dependent diabetes. Due to the
morphological constitution of the patient, the primary
pancreatic lesion could not be evidenced by ultrasonography.
However, a hypo-echoic roundish mass in the abdomen,
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interpreted as one of the metastases, was taken as reference.
This mass was irregularly hypo-echoic with a relatively hyper-
echoic central area and a calculated volume of 52.8 ml (Figure
2A). After two weeks of treatment, the calculated volume of
this lesion was reduced by 30% (Figure 2B). In addition,
thanks to the regimen described above, the patient was able to
discontinue insulin administration and did not require oral anti-
diabetic drugs. Discussion: Unlike other neoplasms,
adenocarcinoma of pancreas is highly resistant to
chemotherapy and targeted therapy (4). Therefore, new
treatment options are urgently needed to improve the survival
of patients with pancreas adenocarcinoma. Since the main
reason for the resilience of pancreatic adenocarcinoma towards
intensive treatment is the cancer-induced immune suppression,
immunotherapy is probably the best candidate among new
treatment strategies (10). In this study we demonstrate that
immunotherapy based on OA bound to GcMAF is effective in
patients with localised or metastatic pancreatic
adenocarcinomas. These results are consistent with clinical
observation accumulated in the past six years demonstrating
that immunotherapy based on GcMAF is highly effective in a
variety of cancers (5, 11-16). The approach described in this
study targets immune suppression that is the main cause of
pancreatic cancer poor prognosis; therefore, it has the potential
for revolutionising the field of pancreatic adenocarcinoma
treatment as it appears highly effective and devoid of harmful
side effects.
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Figure 1. Ultrasonography of adenocarcinoma of the body of
the pancreas before and after OA-GcMAF-based immuno-
therapy. These images refer to clinical case #1 and were taken
before treatment (panel A), and after two weeks (panel B). 
Figure 2. Ultrasonography of a peritoneal lesion associated
with metastatic adenocarcinoma of the pancreas before and
after OA-GcMAF-based immunotherapy. These images refer
to clinical case #2 and were taken before treatment (panel A),
and after two weeks (panel B). 
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Introduction: Hydrogels prepared from star-shaped
poly(ethylene glycol) (PEG) and maleimide-functionalized
heparin provide a potential matrix for use in developing three
dimensional (3D) models. We have previously demonstrated
that these hydrogels support the cultivation of human
umbilical vein endothelial cells (HUVECs). We extend this
body of work to study the ability to create an extracellular
matrix (ECM)-like model to study breast and prostate cancer
cell growth in 3D. Also, we investigate the ability to produce
a tri-culture mimicking tumour angiogenesis with cancer
spheroids, HUVECs and mesenchymal stem cells (MSCs).
Materials and Methods: The breast cancer cell lines MCF-7
and MDA-MB-231, and prostate cancer cell lines LNCaP and
PC3, were seeded into starPEG-heparin hydrogels and grown
for 14 days to analyze the effects of varying hydrogel stiffness
on spheroid development. Resulting hydrogel constructs were
analyzed via proliferation assays, light microscopy and
immunostaining. Cancer cell lines were then seeded into
starPEG-heparin hydrogels functionalized with growth factors
as spheroids with HUVECs and MSCs and grown as a tri-
culture. Cultures were analyzed via immunostaining and
observed using confocal microscopy. Results: Cultures
prepared in MMP-cleavable starPEG-heparin hydrogels
display spheroid formation in contrast to adherent growth on
tissue culture plastic. Small differences were visualized in
cancer spheroid growth between different gel stiffness across
the range of cell lines. Cancer cell lines were able to be co-
cultivated with HUVECs and MSC. Interaction was visualized
between tumours and HUVECs via confocal microscopy.
Further studies intend to further optimize and mimic the ECM
environment of in situ tumour angiogenesis. Discussion: Our
results confirm the suitability of hydrogels constructed from
starPEG-heparin for HUVEC and MSC co-cultivation with
cancer cell lines to study cell-cell and cell-matrix interactions
in a 3D environment. This represents a step forward in the
development of 3D culture models to study the
pathomechanisms of breast and prostate cancer.
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The tumor necrosis factor (TNF) ligand and cognate TNF
receptor superfamily constitute an important
immunoregulatory axis pivotal for the correct execution of
immune responses. Members of these families among others
are involved in induction of cell death in malignant cells as
well as in providing co-stimulatory signals that help mount
effective anti-cancer immune responses. This diverse and
important regulatory role in immunity has sparked great
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